Role of TNFα in pulmonary pathophysiology
Tóm tắt
Tumor necrosis factor alpha (TNFα) is the most widely studied pleiotropic cytokine of the TNF superfamily. In pathophysiological conditions, generation of TNFα at high levels leads to the development of inflammatory responses that are hallmarks of many diseases. Of the various pulmonary diseases, TNFα is implicated in asthma, chronic bronchitis (CB), chronic obstructive pulmonary disease (COPD), acute lung injury (ALI) and acute respiratory distress syndrome (ARDS). In addition to its underlying role in the inflammatory events, there is increasing evidence for involvement of TNFα in the cytotoxicity. Thus, pharmacological agents that can either suppress the production of TNFα or block its biological actions may have potential therapeutic value against a wide variety of diseases. Despite some immunological side effects, anti-TNFα therapeutic strategies represent an important breakthrough in the treatment of inflammatory diseases and may have a role in pulmonary diseases characterized by inflammation and cell death.
Từ khóa
Tài liệu tham khảo
Carswell EA, Old LJ, Kassel RL, Green S, Fiore N, Williamson B: An endotoxin-induced serum factor that causes necrosis of tumors. PNAS (USA) 1975, 72:3666–3670.
Helson L, Green S, Carswell E, Old LJ: Effect of tumour necrosis factor on cultured human melanoma cells. Nature 1975, 258:731–732.
Williamson BD, Carswell EA, Rubin BY, Prendergast JS, Old LJ: Human tumor necrosis factor produced by human B-cell lines: synergistic cytotoxic interaction with human interferon. PNAS (USA) 1983, 80:5397–5401.
Goto T, Ishizaka A, Kobayashi F, Kohno M, Sawafuji M, Tasaka S, Ikeda E, Okada Y, Maruyama I, Kobayashi K: Importance of tumor necrosis factor-alpha cleavage process in post-transplantation lung injury in rats. Am J Respir Crit Care Med 2004, 170:1239–1246.
Beutler B, Cerami A: Cachectin and tumour necrosis factor as two sides of the same biological coin. Nature 1986, 320:584–588.
Aggarwal BB, Kohr WJ, Hass PE, Moffat B, Spencer SA, Henzel WJ, Bringman TS, Nedwin GE, Goeddel DV, Harkins RN: Human tumor necrosis factor. Production, purification, and characterization. J Biol Chem 1985, 260:2345–2354.
Aggarwal BB: Signaling pathways of the TNF superfamily: a double-edged sword. Nat Rev Immunol 2003, 3:745–756.
Locksley RM, Killeen N, Lenardo MJ: The TNF and TNF receptor superfamilies: integrating mammalian biology. Cell 2001, 104:487–501.
Ito H, Koide N, Hassan F, Islam S, Tumurkhuu G, Mori I, Yoshida T, Kakumu S, Moriwaki H, Yokochi T: Lethal endotoxic shock using alpha-galactosylceramide sensitization as a new experimental model of septic shock. Lab Invest 2006, 86:254–261.
Michie HR, Manogue KR, Spriggs DR, Revhaug A, O'Dwyer S, Dinarello A, Cerami A, Wolff SM, Wilmore DW: Detection of circulating tumor necrosis factor after endotoxin administration. N Engl J Med 1988, 318:1481–1486.
Sack M: Tumor necrosis factor-alpha in cardiovascular biology and the potential role for anti-tumor necrosis factor-alpha therapy in heart disease. Pharmacol Ther 2002, 94:1231–35.
Sarzi-Puttini P, Atzeni F, Shoenfeld Y, Ferraccioli G: TNF-alpha, rheumatoid arthritis, and heart failure: a rheumatological dilemma. Autoimmun Rev 2005, 4:153–161.
Kleyn CE, Griffiths CE: Infliximab for the treatment of psoriasis. Expert Opin Biol Ther 2006, 6:797–805.
Danese S, Semeraro S, Armuzzi A, Papa A, Gasbarrini A: Biological therapies for inflammatory bowel disease: research drives clinics. Mini Rev Med Chem 2006, 6:771–784.
Cacquevel M, Lebeurrier N, Cheenne S, Vivien D: Cytokines in neuroinflammation and Alzheimer's disease. Curr Drug Targets 2004, 5:529–34.
Witkamp R, Monshouwer M: Signal transduction in inflammatory processes, current and future therapeutic targets: a mini review. Vet Q 2000, 22:11–16.
Glosli H, Tronstad KJ, Wergedal H, Muller F, Svardal A, Aukrust P, Berge RK, Prydz H: Human TNF-alpha in transgenic mice induces differential changes in redox status and glutathione-regulating enzymes. FASEB J 2002, 16:1450–1452.
Ishii Y, Partridge CA, Del Vecchio PJ, Malik AB: Tumor necrosis factor-alpha-mediated decrease in glutathione increases the sensitivity of pulmonary vascular endothelial cells to H2O2. J Clin Invest 1992, 89:794–802.
Marcho Z, White JE, Higgins PJ, Tsan MF: Tumor necrosis factor enhances endothelial cell susceptibility to oxygen toxicity: role of glutathione. Am J Respir Cell Mol Biol 1991, 5:556–562.
Corda S, Laplace C, Vicaut E, Duranteau J: Rapid Reactive Oxygen Species Production by Mitochondria in Endothelial Cells Exposed to Tumor Necrosis Factor-α Is Mediated by Ceramide. Am J Respir Cell Mol Biol 2001, 24:762–768.
Ferro TJ, Hocking DC, Johnson A: Tumor necrosis factor-alpha alters pulmonary vasoreactivity via neutrophil-derived oxidants. Am J Physiol 1993, 265:L462–471.
Wang Q, Doerschuk CM: Neutrophil-induced changes in the biomechanical properties of endothelial cells: roles of ICAM-1 and reactive oxygen species. J Immunol 2000, 164:6487–6494.
Mukherjee TK, Mukhopadhyay S, Hoidal JR: The Role of Reactive Oxygen Species in TNFα-Dependent Expression of the Receptor for Advanced Glycation End Products in Human Umbilical Vein Endothelial Cells. BBA 2005, 1744:213–223.
Deshpande SS, Angkeow P, Huang J, Ozaki M, Irani K: Rac1 inhibits TNF-alpha-induced endothelial cell apoptosis: dual regulation by reactive oxygen species. FASEB J 2000, 14:1705–1714.
Atsuta J, Sterbinsky SA, Plitt J, Schwiebert LM, Bochner BS, Schleimer RP: Phenotyping and cytokine regulation of the BEAS-2B human bronchial epithelial cell: demonstration of inducible expression of the adhesion molecules VCAM-1 and ICAM-1. Am J Respir Cell Mol Biol 1997, 17:571–582.
Kampf C, Relova AJ, Sandler S, Roomans GM: Effects of TNF-alpha, IFN-gamma and IL-beta on normal human bronchial epithelial cells. Eur Respir J 1999, 14:84–91.
Tillie-Leblond I, Guery BP, Janin A, Leberre R, Just N, Pittet JF, Tonnel AB, Gosset P: Chronic bronchial allergic inflammation increases alveolar liquid clearance by TNF-alpha-dependent mechanism. Am J Physiol Lung Cell Mol Physiol 2002, 283:L1303-L1309.
Burgess JK, Blake AE, Boustany S, Johnson PR, Armour CL, Black JL, Hunt NH, Hughes JM: CD40 and OX40 ligand are increased on stimulated asthmatic airway smooth muscle. J Allergy Clin Immunol 2005, 115:302–308.
Hughes JM, Stringer RS, Black JL, Armour CL: The effects of tumour necrosis factor alpha on mediator release from human lung. Pulm Pharmacol 1995, 8:31–36.
Wagner EM: TNF-alpha induced bronchial vasoconstriction. Am J Physiol Heart Circ Physiol 2000, 279:H946–951.
Choi IW, Sun-Kim , Kim YS, Ko HM, Im SY, Kim JH, You HJ, Lee YC, Lee JH, Park YM, Lee HK: TNF-alpha induces the late-phase airway hyperresponsiveness and airway inflammation through cytosolic phospholipase A(2) activation. J Allergy Clin Immunol 2005, 116:537–543.
Sakai H, Otogoto S, Chiba Y, Abe K, Misawa M: TNF-alpha augments the expression of RhoA in the rat bronchus. J Smooth Muscle Res 2004, 40:25–34.
Rudmann DG, Moore MW, Tepper JS, Aldrich MC, Pfeiffer JW, Hogenesch H, Tumas DB: Modulation of allergic inflammation in mice deficient in TNF receptors. Am J Physiol Lung Cell Mol Physiol 2000, 279:L1047-L1057.
Hessel EM, Van Oosterhout AJ, Van ark I, Van Esch B, Hofman G, Van Loveren H, Savelkoul HF, Nijkamp FP: Development of airway hyperresponsiveness is dependent on interferon-gamma and independent of eosinophil infiltration. Am J Respir Cell Mol Biol 1997, 16:325–334.
Leckie MJ: Anti-interleukin-5 monoclonal antibodies: preclinical and clinical evidence in asthma models. Am J Respir Med 2003, 2:245–259.
Flood-Page PT, Menzies-Gow AN, Kay AB, Robinson DS: Eosinophil's Role Remains Uncertain as Anti-Interleukin-5 only Partially Depletes Numbers in Asthmatic Airway. Am J Respir Crit Care Med 2003, 167:199–204.
Borish LC, Nelson HS, Corren J, Bensch G, Busse WW: Efficacy of soluble IL-4 receptor for the treatment of adults with asthma. J Allergy Clin Immunol 2001, 107:963–970.
Grashoff WF, Sont JK, Sterk PJ, Hiemstra PS, de Boer WI, Stolk J, Han J, van Krieken JM: Chronic obstructive pulmonary disease: the role of bronchiolar mast cells and macrophages. Am J Pathol 1997, 151:1785–1790.
O'Shaughnessy TC, Ansari TW, Barnes C, Jeffery PK: Inflammation in bronchial biopsies of subjects with chronic bronchitis: inverse relationship of CD8+ T lymphocytes with FEV 1 . Am J Respir Crit Care Med 1997, 155:852–857.
Szilasi M, Dolinay T, Nemes Z, Strausz J: Pathology of chronic obstructive pulmonary disease. Pathol Oncol Research 2006, 12:52–60.
Mannino DM: COPD: epidemiology, prevalence, morbidity and mortality, and disease heterogeneity. Chest 2002, 121:121S-126S.
Lundblad LK, Thompson-Figueroa J, Leclair T, Sullivan MJ, Poynter ME, Irvin CG, Bates JH: TNF-{alpha} Over-expression in Lung Disease: a Single Cause Behind a Complex Phenotype. Am J Respir Crit Care Med 2005, 171:1363–1371.
Huang SL, Su CH, Chang SC: Tumor necrosis factor-alpha gene polymorphism in chronic bronchitis. Am J Respir Crit Care Med 1997, 156:1436–1439.
Chierakul N, Wongwisutikul P, Vejbaesya S, Chotvilaiwan K: Tumor necrosis factor-alpha gene promoter polymorphism is not associated with smoking-related COPD in Thailand. Respirology 2005, 10:36–39.
Jiang L, He B, Zhao MW, Ning LD, Li XY, Yao WZ: Association of gene polymorphisms of tumour necrosis factor-alpha and interleukin-13 with chronic obstructive pulmonary disease in Han nationality in Beijing. Chin Med J (Engl) 2005, 118:541–547.
Dal Negro RW, Micheletto C, Tognella S, Visconti M, Guerriero M, Sandri MF: A Two-stage Logistic Model Based on the Measurement of Pro-Inflammatory Cytokines in Bronchial Secretions for Assessing Bacterial, Viral and Non-infectious Origin of COPD Exacerbations. J COPD 2005, 2:7–16.
Niederman MS, Fein AM: Sepsis syndrome, the adult respiratory distress syndrome, and nosocomial pneumonia. A common clinical sequence. Clin Chest Med 1990, 11:633–656.
Leeper-Woodford SK, Carey PD, Byrne K, Jenkins JK, Fisher BJ, Blocher C, Sugerman HJ, Fowler AA 3rd: Tumor necrosis factor. Alpha and beta subtypes appear in circulation during onset of sepsis-induced lung injury. Am Rev Respir Dis 1991, 143:1076–1082.
Sheridan BC, McIntyre RC, Meldrum DR, Fullerton DA: Pentoxifylline treatment attenuates pulmonary vasomotor dysfunction in acute lung injury. J Surg Res 1997, 71:150–154.
Meduri GU, Kohler G, Headley S, Tolley E, Stentz F, Postlethwaite A: Inflammatory cytokines in the BAL of patients with ARDS. Persistent elevation over time predicts poor outcome. Chest 1995, 108:1303–1314.
Borrelli E, Roux-Lombard P, Grau GE, Giardin E, Ricou B, Dayer J, Suter PM, et al.: Plasma concentrations of cytokines, their soluble receptors, and antioxidant vitamins can predict the development of multiple organ failure in patients at risk. Crit Care Med 1996, 24:392–397.
Parsons PE, Matthay MA, Ware LB, Eisner MD: National Heart, Lung, Blood Institute Acute Respiratory Distress Syndrome Clinical Trials Network. Elevated plasma levels of soluble TNF receptors are associated with morbidity and mortality in patients with acute lung injury. Am J Physiol Lung Cell Mol Physiol 2005, 288:L426–431.
van Riemsdijk-van Overbeeke IC, Baan CC, Niesters HG, Hesse CJ, Loonen EH, Balk AH, Maat AP, Weimar W: The TNF-alpha system in heart failure and after heart transplantation: plasma protein levels, mRNA expression, soluble receptors and plasma buffer capacity. Eur Heart J 1999, 20:833–840.
Gong MN, Wei Z, Xu LL, Miller DP, Thompson BT, Christiani DC: Polymorphism in the surfactant protein-B gene, gender, and the risk of direct pulmonary injury and ARDS. Chest 2004, 125:203–211.
Veldhuizen EJ, Haagsman HP: Role of pulmonary surfactant components in surface film formation and dynamics. BBA 2000, 1467:255–270.
Enhorning G, Duffy LC, Welliver R: Pulmonary surfactant maintains patency of conducting airways in the rat. Am J Respir Crit Care Med 1995, 151:554–556.
Berhane K, Margana RK, Boggaram V: Characterization of rabbit SP-B promoter region responsive to downregulation by tumor necrosis factor-alpha. Am J Physiol Lung Cell Mol Physiol 2000, 279:L806–814.
Miakotina OL, Snyder JM: TNF-alpha inhibits SP-A gene expression in lung epithelial cells via p38 MAPK. Am J Physiol Lung Cell Mol Physiol 2002, 283:L418–427.
Meiners I, Hauschildt S, Nieber K, Munch G: Pentoxyphylline and propentophylline are inhibitors of TNF-alpha release in monocytes activated by advanced glycation endproducts. J Neural Transm 2004, 111:441–447.
Coimbra R, Melbostad H, Loomis W, Porcides RD, Wolf P, Tobar M, Hoyt DB: LPS-induced acute lung injury is attenuated by phosphodiesterase inhibition: effects on proinflammatory mediators, metalloproteinases, NF-kappaB, and ICAM-1 expression. J Trauma 2006, 60:115–125.
Moreira AL, Sampaio EP, Zmuidzinas A, Frindt P, Smith KA, Kaplan G: Thalidomide exerts its inhibitory action by enhancing mRNA degradation. J Exp Med 1993, 177:1675–1680.
Tracey KJ: Suppression of TNF and other proinflammatory cytokines by the tetravalent guanylhydrazone CNI-1493. Prog Clin Biol Res 1998, 397:335–343.
Gearing AJ, Beckett P, Christodoulou M, Churchill M, Clements J, Davidson AH, Drummond AH, Galloway WA, Gilbert R, Gordon JL, et al.: Processing of tumour necrosis factor α precursor by metalloproteinases. Nature 1994, 370:555–557.
Berry MA, Hargadon B, Shelley M, Parker D, Shaw DE, Green RH, Bradding P, Brightling CE, Wardlaw AJ, Pavord ID: Evidence of a role of tumor necrosis factor alpha in refractory asthma. N Engl J Med 2006, 354:697–708.
Dinarello CA: Differences between anti-tumor necrosis factor-alpha monoclonal antibodies and soluble TNF receptors in host defense impairment. J Rheumatol Suppl 2005, 74:40–47.
Guery BP, Welsh DA, Viget NB, Robriquet L, Fialdes P, Mason CM, Beaucaire G, Bogby GJ, Neviere R: Ventilation-induced lung injury is associated with an increase in gut permeability. Shock 2003, 19:559–563.
Bhalla DK, Reinhart PG, Bai C, Gupta SK: Amelioration of ozone-induced lung injury by anti-tumor necrosis factor-alpha. Toxico Sci 2002, 69:400–408.
Howarth PH, Babu KS, Arshad HS, Lau L, Buckley M, McConnel W, Beckett P, Ali M, Cahuhan A, Wilson SJ, Reynolds A, Davies DE, Holgate ST: Tumour necrosis factor (TNFalpha) as a novel therapeutic target in symptomatic corticosteroid dependent asthma. Thorax 2005, 60:1012–1018.
Fullmer JJ, Fan LL, Dishop MK, Rodgers C, Krance R: Successful treatment of bronchiolitis obliterans in a bone marrow transplant patient with tumor necrosis factor-alpha blockade. Pediatrics 2005, 116:767–770.
van der Vaart H, Koeter GH, Postma DS, Kauffman HF, Hacken NH: First study of infliximab treatment in patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2005, 172:465–469.
Antoniu SA: Infliximab for chronic obstructive pulmonary disease: towards a more specific inflammation targeting? Expert Opin Investig Drugs 2006, 15:181–184.
de Boer WI: Perspectives for cytokine antagonist therapy in COPD. Drug Discov Today 2006, 10:93–106.
Bongartz T, Sutton AJ, Sweeting MJ, Iain Buchan I, Matteson EL, Montori V: Anti-TNF Antibody Therapy in Rheumatoid Arthritis and the Risk of Serious Infections and Malignancies. JAMA 2006, 295:2275–2285.
Panagi S, Palka W, Korelitz BI, Taskin M, Lessnau KD: Diffuse alveolar hemorrhage after infliximab treatment of Crohn's disease. Inflamm Bowel Disease 2004, 10:274–277.